Further, by employing universal and sensitive examination for KIT p.D816V in PBL, we highlight the potency of KIT screening in PBL to find CM patients at risk for systemic clonal MC disorder and further highlight the use of KIT screening as a biomarker in clinical practice of children with CM. This evidence concerns the gene KIT and cutaneous mastocytosis.